Parkinson's Foundation PD GENEration Genetic Registry

July 12, 2023 updated by: Parkinson's Foundation
Development of a central repository for PD-related genomic data for future research.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The purpose of this study is to develop a central repository for PD-related genomic data by individuals who consent to deposit their data and bank their residual DNA obtained through clinical genetic testing for future research use.

Study Type

Observational

Enrollment (Estimated)

15000

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Arizona
      • Chandler, Arizona, United States, 85286
        • Recruiting
        • MD First Research
        • Contact:
        • Principal Investigator:
          • Hemant Pandey, MD
      • Phoenix, Arizona, United States, 85013
    • Arkansas
      • Fayetteville, Arkansas, United States, 72701
        • Recruiting
        • University of Arkansas
        • Contact:
        • Principal Investigator:
          • Rohit Dhall, MD
    • California
      • La Jolla, California, United States, 92093
        • Recruiting
        • University of California San Diego (UCSD)
        • Principal Investigator:
          • Irene Litvan, MD
        • Contact:
      • San Francisco, California, United States, 94143
        • Recruiting
        • University of California San Francisco (UCSF)
        • Contact:
        • Principal Investigator:
          • Jill Ostrem, MD
    • Florida
      • Aventura, Florida, United States, 33180
        • Recruiting
        • Aventura Neurology - Visionary Investigators Network
        • Contact:
        • Principal Investigator:
          • Julie Schwartzbard, MD
      • Boca Raton, Florida, United States, 33486
        • Recruiting
        • Parkinson's Disease & Movement Disorder Center of Boca Raton
        • Contact:
        • Principal Investigator:
          • Stuart Isaacson, MD
      • Miami, Florida, United States, 33131
        • Recruiting
        • University of Miami
        • Principal Investigator:
          • Carlos Singer, MD
        • Contact:
          • Lucila Hernandez
          • Phone Number: 305-243-1160
        • Principal Investigator:
          • Ihtsham Haq, MD
        • Sub-Investigator:
          • Henry Moore, MD
    • Georgia
      • Atlanta, Georgia, United States, 30314
        • Recruiting
        • Morehouse College
        • Principal Investigator:
          • Chantale Branson, MD
        • Contact:
    • Illinois
      • Chicago, Illinois, United States, 60612
        • Recruiting
        • Rush University
        • Principal Investigator:
          • Deborah Hall, MD
        • Contact:
      • Evanston, Illinois, United States, 60208
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Recruiting
        • Indiana University
        • Contact:
        • Principal Investigator:
          • Elizabeth Zauber, MD
    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Recruiting
        • Beth Israel Deaconess Medical Center (BIDMC)
        • Principal Investigator:
          • David Simon, MD
        • Contact:
      • Boston, Massachusetts, United States, 02136
        • Recruiting
        • St. Elizabeth's Medical Center
        • Contact:
        • Principal Investigator:
          • Eleni Okeanis Vaou, MD
    • Minnesota
      • Golden Valley, Minnesota, United States, 55427
        • Recruiting
        • Struthers Parkinson's Center - HealthPartners Park Nicollet
        • Principal Investigator:
          • Martha Nance, MD
        • Contact:
    • Washington
      • Spokane, Washington, United States, 99202
        • Recruiting
        • Inland Northwest Research
        • Contact:
        • Principal Investigator:
          • Jason Aldred, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Any person with probable diagnosis of Parkinson's disease according to the Movement Disorders Society criteria.

Description

Inclusion Criteria:

  • Study Population 1: PWP (open for recruitment)

    1. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's Disease: probable diagnosis.
    2. Willingness to undergo genetic testing, and choose to be informed of genetic testing results for GBA, LRRK2 and 5 additional PD related genes (SNCA, VPS35, PRKN, PINK-1, PARK7).
    3. Capacity to give full informed consent in writing or electronically, and have read and signed the informed consent forms (ICFs) based on site clinician's determination.
    4. Able to perform study activities (including completion of either online, in-person or paper surveys).

Study Population 2: People at risk of developing PD (not open for recruitment)

1. Family members of Study Population 1 may be invited to participate in the study if confirmatory genetic testing is deemed necessary by the genetic testing laboratory.

Exclusion Criteria:

  1. Diagnosis of an atypical parkinsonian disorder (i.e., multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies, corticobasal syndrome), including that due to medications, metabolic disorders, encephalitis, cerebrovascular disease, or normal pressure hydrocephalus.
  2. Individuals who have received a blood transfusion within the past 3 months.
  3. Individuals who have active hematologic malignancies such as lymphoma or leukemia.
  4. Individuals who have had a bone marrow transplant within the past 5 years.
  5. Under the age of 18

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of Parkinson's related genetic mutations in an convenience cohort
Time Frame: 6 months
Identify people with Parkinson's who have genetic mutations to advance basic science and clinical research.
6 months
Educating people with Parkinson's of their genetic mutation status through genetic testing and counseling
Time Frame: 6 months
People who are informed of their genetic status may be empowered to learn more about their disease and participant in clinical research.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Parkinson's Foundation

Collaborators

Indiana University
The Parkinson Study Group
Fulgent Genetics

Investigators

  • Principal Investigator: James Beck, PhD, Parkinson's Foundation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 20, 2020

Primary Completion (Estimated)

December 31, 2024

Study Completion (Estimated)

June 1, 2025

Study Registration Dates

First Submitted

July 29, 2021

First Submitted That Met QC Criteria

July 29, 2021

First Posted (Actual)

August 6, 2021

Study Record Updates

Last Update Posted (Actual)

July 14, 2023

Last Update Submitted That Met QC Criteria

July 12, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PDGENE-PF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson's Disease

Clinical Trials on Lab Assay for seven genetic variants for Parkinson's Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe